Drug
Talimogene Laherparepvec
Talimogene Laherparepvec: highest development phase Phase 1, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Talimogene Laherparepvec NCT02626000 | Phase 1 | Carcinoma of the Head and Neck |
Latest
No recent events.
Follow Talimogene Laherparepvec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.